Evidence mapPaperPMID 39904520Full record

ArticleBMJ open diabetes research & care2025

Association of glycemic control with Long COVID in patients with type 2 diabetes: findings from the National COVID Cohort Collaborative (N3C).

Samuel Soff, Yun Jae Yoo, Carolyn Bramante, Jane E B Reusch, Jared Davis Huling, Margaret A Hall, Daniel Brannock, Til Sturmer, Zachary Butzin-Dozier, Rachel Wong and 2 more

Abstract read
In one paragraph

Article in BMJ open diabetes research & care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Pre-pandemic diabetes and risk of long COVID: longitudinal evidence.Journal of diabetes and metabolic disorders · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Samuel SoffStony Brook University Renaissance School of Medicine, Stony Brook, New York, USA.ORCID http://orcid.org/0000-0001-5851-6075
Yun Jae YooDepartment of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0003-2144-8480
Carolyn BramanteDivision of General Internal Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA.ORCID http://orcid.org/0000-0001-5858-2080
Jane E B ReuschDivision of Endocrinology, Metabolism and Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID http://orcid.org/0000-0001-8620-1003
Jared Davis HulingBiostatistics, University of Minnesota Twin Cities, Minneapolis, Minnesota, USA.ORCID http://orcid.org/0000-0003-0670-4845
Margaret A HallDepartment of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0002-6263-440X
Daniel BrannockRTI International, Research Triangle Park, North Carolina, USA.ORCID http://orcid.org/0000-0001-8095-547X
Til SturmerDepartment of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID http://orcid.org/0000-0002-9204-7177
Zachary Butzin-DozierSchool of Public Health, University of California Berkeley, Berkeley, California, USA.ORCID http://orcid.org/0000-0001-6419-0008
Rachel Wong *Department of Biomedical Informatics, Stony Brook University Renaissance School of Medicine, Stony Brook, New York, USA.ORCID http://orcid.org/0000-0003-3108-7324
Richard Moffitt *Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA richard.austin.moffitt@emory.edu.ORCID http://orcid.org/0000-0003-2723-5902
N3C Consortium

Funding

SUPPORT SERVICES FOR THE PREVENTION AND TREATMENT THROUGH A COMPREHENSIVE CARE CONTINUUM FOR HIV-AFFECTED ADOLESCENTS IN RESOURCE CONSTRAINED SETTINGS IMPLEMENTATION SCIENCE NETWORK75N94023D00001 · WESTAT, INC. · 2025 to 2025
$4.5M
Resource to Advance Pediatrics and HIV Prevention Science (RAPPS): Quality Assurance/Quality Control (QA/QC) Support75N93023D00001 · ADVANCED BIOSCIENCE LABORATORIES, INC. · 2025 to 2025
$2.7M
RADX INNOVATION FUNNEL FOR HEALTH TECHNOLOGIES - AWARD MANAGEMENT, TASK ORDER 00575N92023D00001 · VENTUREWELL · 2025 to 2025
$1.5M
CLC NIH HHS 75N90023D00001NHLBI NIH HHS 75N92023D00001NICHD NIH HHS 75N94023D00001NIDA NIH HHS 75N93023D00001NIDA NIH HHS 75N95021D00001NIDDK NIH HHS R01 DK130351ORFDO NIH HHS 75N99023D00001
6 · The paper itself

Abstract

introductionElevated glycosylated hemoglobin (HbA1c) in individuals with type 2 diabetes is associated with increased risk of hospitalization and death after acute COVID-19, however the effect of HbA1c on Long COVID is unclear.

objectiveEvaluate the association of glycemic control with the development of Long COVID in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND

methodsWe conducted a retrospective cohort study using electronic health record data from the National COVID Cohort Collaborative. Our cohort included individuals with T2D from eight sites with longitudinal natural language processing (NLP) data. The primary outcome was death or new-onset recurrent Long COVID symptoms within 30-180 days after COVID-19. Symptoms were identified as keywords from clinical notes using NLP in respiratory, brain fog, fatigue, loss of smell/taste, cough, cardiovascular and musculoskeletal symptom categories. Logistic regression was used to evaluate the risk of Long COVID by HbA1c range, adjusting for demographics, body mass index, comorbidities, and diabetes medication. A COVID-negative group was used as a control.

resultsAmong 7430 COVID-positive patients, 1491 (20.1%) developed symptomatic Long COVID, and 380 (5.1%) died. The primary outcome of death or Long COVID was increased in patients with HbA1c 8% to <10% (OR 1.20, 95% CI 1.02 to 1.41) and ≥10% (OR 1.40, 95% CI 1.14 to 1.72) compared with those with HbA1c 6.5% to <8%. This association was not seen in the COVID-negative group. Higher HbA1c levels were associated with increased risk of Long COVID symptoms, especially respiratory and brain fog. There was no association between HbA1c levels and risk of death within 30-180 days following COVID-19. NLP identified more patients with Long COVID symptoms compared with diagnosis codes.

conclusionPoor glycemic control (HbA1c≥8%) in people with T2D was associated with higher risk of Long COVID symptoms 30-180 days following COVID-19. Notably, this risk increased as HbA1c levels rose. However, this association was not observed in patients with T2D without a history of COVID-19. An NLP-based definition of Long COVID identified more patients than diagnosis codes and should be considered in future studies.

Indexed as

COVID-19Diabetes Mellitus, Type 2Glycemic ControlAgedBlood GlucoseElectronic Health RecordsFemaleGlycated HemoglobinHumansMaleMiddle AgedRetrospective StudiesRisk FactorsSARS-CoV-2United StatesBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanCOVID-19DatabaseDiabetes ComplicationsDiabetes Mellitus, Type 2

Identifiers

PMID39904520
PMCPMC11795369

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.